Interim Results from PAZOREAL: A Non-interventional Study to Assess Effectiveness and Safety of Pazopanib and Everolimus in the Changine mRCC Treatment Landscape. 15. Januar 2018 Bedke, J., Welslau, M., Boegemann, M., Schostak, M., Hering-Schubert, C., Petzoldt, A., Wolf, T., Schleicher, J., Doehn, C., Grüllich, C., Grünwald, V., Steiner, T., Ehness, R., Klein, D., Medinger, T., Goebell, P., 2017. Ann Oncol 28 (Supplement 5)(899P), 318–319. doi:10.1093/annonc/mdx371 Abstract Influence of comorbidities on clinical outcome in patients (pts) receiving chemotherapy (CT) + bevacizumab (BEV) for primary advanced ovarian cancer (OC). Woopen, H., Wimberger, P., Mustea, A., Oskay-Oezcelik, G., Keller, M., Richter, R., Harde, J., Klawitter, S., Wegenaer, A., Tomé, O., Sehouli, J., 2017. Ann Oncol… Weiterlesen Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of Sorafenib-Pazopanib versus Pazopanib-Sorafenib in the treatment of metastatic renal cell carcinoma (SWITCH-II). Retz, M., Bedke, J., Herrmann, E., Grimm, M., Zimmermann, U., Müller, L., Leiber, C., Teber, D., Wirth, M., Bolenz, C., van Alphen, R., De Santis,… Weiterlesen